Search Results - "Rachor, Johannes"

Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells by Gierlich, Philipp, Lex, Veronika, Technau, Antje, Keupp, Anne, Morper, Lorenz, Glunz, Amelie, Sennholz, Hanno, Rachor, Johannes, Sauer, Sascha, Marcu, Ana, Grigoleit, Götz Ulrich, Wölfl, Matthias, Schlegel, Paul G., Eyrich, Matthias

“…Mature dendritic cells (DCs) represent cellular adjuvants for optimal antigen presentation in cancer vaccines. Recently, a combination of prostaglandin E 2…”
Get full text

Stimulating surface molecules, Th1-polarizing cytokines, proven trafficking—a new protocol for the generation of clinical-grade dendritic cells by Tan, Sen Mui, Kapp, Markus, Flechsig, Christin, Kapp, Kerstin, Rachor, Johannes E, Eyrich, Matthias, Loeffler, Juergen, Einsele, Hermann, Grigoleit, Goetz U

“…Abstract Background aims Dendritic cells (DC) have been vigorously investigated as an immunological basis for therapeutic vaccination against cancer and…”
Get full text

IMMU-07. Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial Treg depletion and double checkpoint blockade in children with relapsed high-grade gliomas by Eyrich, Matthias, Krauss, Jürgen, Ghaffari, Maryam, Caruana, Ignazio, Rachor, Johannes, Monoranu, Camelia-Maria, Bison, Brigitte, Rückriegel, Stefan, Wölfl, Matthias, Miller, Elisabeth, Schlegel, Paul-Gerhardt, Kramm, Christof

“…Relapses of high-grade gliomas show an aggressive course and survival 6 months after (sub-)total re-resection was only 62% in former HIT-HGG trials…”
Get full text

Prostaglandin E 2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8 + T cells by Gierlich, Philipp, Lex, Veronika, Technau, Antje, Keupp, Anne, Morper, Lorenz, Glunz, Amelie, Sennholz, Hanno, Rachor, Johannes, Sauer, Sascha, Marcu, Ana, Grigoleit, Götz Ulrich, Wölfl, Matthias, Schlegel, Paul G, Eyrich, Matthias

“…Mature dendritic cells (DCs) represent cellular adjuvants for optimal antigen presentation in cancer vaccines. Recently, a combination of prostaglandin E (PGE…”
Get full text

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS by Eyrich, Matthias, Krauss, Jürgen, Rachor, Johannes, Monoranu, Camelia, Bison, Brigitte, Löhr, Mario, Rückriegel, Stefan, Wölfl, Matthias, Miller, Elisabeth, Schlegel, Paul G, Kramm, Christof

“…Efficacy of therapeutic dendritic cell vaccines (DCV) can be limited by immunosuppressive mechanisms in the micromilieu of high-grade gliomas. In the…”
Get full text

High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion by Löhr, Mario, Freitag, Benjamin, Technau, Antje, Krauss, Jürgen, Monoranu, Camelia-Maria, Rachor, Johannes, Lutz, Manfred B., Hagemann, Carsten, Kessler, Almuth F., Linsenmann, Thomas, Wölfl, Matthias, Ernestus, Ralf-Ingo, Engelhardt, Sabrina, Gelbrich, Götz, Schlegel, Paul G., Eyrich, Matthias

“…High-grade gliomas (HGG) exert systemic immunosuppression, which is of particular importance as immunotherapeutic strategies such as therapeutic vaccines are…”
Get full text

High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T reg depletion by Löhr, Mario, Freitag, Benjamin, Technau, Antje, Krauss, Jürgen, Monoranu, Camelia-Maria, Rachor, Johannes, Lutz, Manfred B, Hagemann, Carsten, Kessler, Almuth F, Linsenmann, Thomas, Wölfl, Matthias, Ernestus, Ralf-Ingo, Engelhardt, Sabrina, Gelbrich, Götz, Schlegel, Paul G, Eyrich, Matthias

“…High-grade gliomas (HGG) exert systemic immunosuppression, which is of particular importance as immunotherapeutic strategies such as therapeutic vaccines are…”
Get full text

CD40-Licensing Of Human Dendritic Cells Further Matures Tnfa-Treated Dcs But Does Not Mediate Resistance Against Inhibition Of T-Cell Proliferation By TREG by Eyrich, Matthias, Rachor, Johannes, Blume, Marissa, Becker, Isabelle, Stumpf, Anne, Wajant, Harald, Wolfl, Matthias, Schlegel, Paul G., Lutz, Manfred

“…Vaccination with cytokine-matured dendritic cells (DCs), loaded with autologous tumor lysate, represents a promising strategy in cancer immunotherapy, however,…”
Get full text

Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group by van Gool, Stefaan W, Holm, Stefan, Rachor, Johannes, Adamson, Lars, Technau, Antje, Maass, Eberhard, Frühwald, Michael C, Schlegel, Paul G, Eyrich, Matthias

“…Abstract Background aims Atypical rhabdoid/teratoid tumors (AT/RT) are the most common brain tumors in infants and associated with a dismal prognosis. Although…”
Get full text

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells by Eyrich, Matthias, Schreiber, Susanne C, Rachor, Johannes, Krauss, Jürgen, Pauwels, Femke, Hain, Johannes, Wölfl, Matthias, Lutz, Manfred B, de Vleeschouwer, Steven, Schlegel, Paul G, Van Gool, Stefaan W

“…Abstract Background and aims One of the major challenges of dendritic cell (DC) vaccination is the establishment of harmonized DC production protocols. Here,…”
Get full text

Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives by Eyrich, Matthias, Rachor, Johannes, Schreiber, Susanne C, Wölfl, Matthias, Schlegel, Paul G

“…Immunotherapy of malignant gliomas with autologous dendritic cells (DCs) in addition to surgery and radiochemotherapy has been a focus of intense research…”
Get full text